According to GlobalData’s medical device pipeline database, 34 Central Nervous System devices are in various stages of development globally. GlobalData’s report Central Nervous System provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 21 are in active development, while the remaining 13 are in an inactive stage of development. There are 11 products in the early stages of development, and the remaining ten are in the late stages of development.
Diagnostic imaging devices are used for the visualization of structural and functional patterns of organs or tissues. Computed Tomography (CT) Systems, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems, X-ray Systems, Bone Densitometers, Angio Suites, Contrast Media Injectors, Accessories, Contrast Agents, Radiopharmaceuticals and C-arms are covered under this market. Central Nervous System includes radiopharmaceutical agents that are used to deliver radiation to tumors in the CNS. This is called targeted therapy. It is used for diagnosing and treating diseases of the CNS.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Central Nervous System pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Central Nervous System devices. Overall, most of these Central Nervous System pipeline devices are being developed by private entities.
Key players involved in the active development of Central Nervous System include Centre for Addiction and Mental Health, Cell>Point, China Isotope & Radiation, MAP Medical Technologies, Helmholtz Center Dresden Rossendorf, Johns Hopkins University, Life Molecular Imaging, CereMark Pharma, Massachusetts General Hospital and Monash University.
For a complete picture of the developmental pipeline for Central Nervous System devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.